Geron Corporation (Nasdaq:GERN) announced today that it will host an analyst and investor meeting in New York City on Tuesday, July 17, 2007.

At the meeting, Alan B. Colowick, M.D., M.P.H., president of Oncology, and Fabio Benedetti, M.D., senior vice president of Oncology, Clinical Development, will give an in-depth presentation of Geron’s cancer development programs and clinical trials strategy for GRN163L, the company’s telomerase inhibitor drug, and GRNVAC1, its telomerase cancer vaccine. A question-and-answer session and discussion will follow the formal presentation.

The Webcast of the audio and slide presentation, including the Q&A, will begin at 12:15 p.m. EDT and conclude at approximately 2 p.m. EDT. The Webcast will be available through a link that will be posted on the Conferences page in the Investor Relations section of Geron’s Website at http://www.geron.com/showpage.asp?code=invecc. A replay of this Webcast will be available at this site for 30 days.

“We are pleased to have an opportunity to present and discuss our cancer programs in-depth, including our results to date and our clinical development plans,” said Thomas B. Okarma, M.D., Ph.D., Geron’s president and chief executive officer. “We are excited about the promise of our drug and vaccine therapy and look forward to sharing our thinking about clinical trials with the investment community.”

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

Contacts:

Geron Corporation
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@geron.com
or
Russo Partners, LLC
David Schull, 858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@russopartnersllc.com